Glypican-1 targeted antibody-based therapy induces preclinical antitumor activity against esophageal squamous cell carcinoma

Esophageal squamous cell carcinoma (ESCC) has a poor prognosis despite the development of multimodal therapy. Expression of glypican-1 (GPC1) has been reported to be elevated in a subset of patients with ESCC and associated with chemoresistance. This study aimed to determine the association of GPC1...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncotarget
Hauptverfasser: Harada, Emi, Serada, Satoshi, Fujimoto, Minoru, Takahashi, Yusuke, Takahashi, Tsuyoshi, Hara, Hisashi, Nakatsuka, Rie, Sugase, Takahito, Nishigaki, Takahiko, Saito, Yurina, Hiramatsu, Kosuke, Nojima, Satoshi, Mitsuo, Risa, Ohkawara, Tomoharu, Morii, Eiichi, Mori, Masaki, Doki, Yuichiro, Kaneda, Yasufumi, Naka, Tetsuji
Format: Artigo
Sprache:Inglês
Veröffentlicht: Impact Journals LLC 2017
Schlagworte:
Research Paper
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5421884/
https://ncbi.nlm.nih.gov/pubmed/28445969
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.15799
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge